| SD-Fhem1+/- |
blood hemoglobin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood hemoglobin amount |
male |
0 days
| 3 |
1450.0 |
g/dl |
40.41 |
70.0 |
automated blood analysis |
0.0 |
0 |
104855 |
2989 |
| SD-Fhem1+/- |
blood hemoglobin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood hemoglobin amount |
female |
0 days
| 3 |
1450.0 |
g/dl |
40.41 |
70.0 |
automated blood analysis |
0.0 |
0 |
104856 |
2989 |
| SD-Fhem1+/- |
mean corpuscular hemoglobin |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood hemoglobin amount |
male |
0 days
| 3 |
16.2 |
pg |
0.29 |
0.5 |
automated blood analysis |
0.0 |
0 |
104879 |
2989 |
| SD-Fhem1+/- |
blood lymphocyte count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
lymphocyte quantity |
male |
0 days
| 3 |
1.7 |
x 1000 cells/ul |
0.52 |
0.9 |
automated blood analysis |
0.0 |
0 |
104899 |
2989 |
| SD-Fhem1+/- |
blood monocyte count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
leukocyte quantity |
male |
0 days
| 3 |
0.4 |
x 1000 cells/ul |
0.29 |
0.5 |
automated blood analysis |
0.0 |
0 |
104903 |
2989 |
| SD-Fhem1+/- |
red blood cell distribution width- standard deviation |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte size trait |
female |
0 days
| 3 |
25.6 |
% |
0.69 |
1.2 |
automated blood analysis |
0.0 |
0 |
104912 |
2989 |
| SD-Fhem1+/- |
blood gamma-glutamyltransferase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood gamma-glutamyltransferase amount |
female |
0 days
| 3 |
1.8 |
U/l |
0.29 |
0.5 |
automated blood analysis |
0.0 |
0 |
104936 |
2989 |
| SD-Fhem1+/- |
blood alkaline phosphatase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood alkaline phosphatase amount |
male |
0 days
| 3 |
38.0 |
U/l |
5.43 |
9.4 |
automated blood analysis |
0.0 |
0 |
104940 |
2989 |
| SD-Fhem1+/- |
plasma direct bilirubin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood bilirubin amount |
male |
0 days
| 3 |
0.3 |
umol/l |
0.12 |
0.2 |
automated blood analysis |
0.0 |
0 |
104947 |
2989 |
| SD-Fhem1+/- |
blood albumin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood albumin amount |
female |
0 days
| 3 |
373.0 |
g/dl |
12.7 |
22.0 |
automated blood analysis |
0.0 |
0 |
104960 |
2989 |
| SD-Fhem1+/- |
blood uric acid level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood uric acid amount |
male |
0 days
| 3 |
3.07 |
mg/dl |
0.14 |
0.24 |
automated blood analysis |
0.0 |
0 |
104975 |
2989 |
| SD-Fhem1+/- |
mean platelet volume |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
platelet size trait |
male |
0 days
| 3 |
8.1 |
fl |
0.29 |
0.5 |
automated blood analysis |
0.0 |
0 |
104867 |
2989 |
| SD-Fhem1+/- |
mean corpuscular volume |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte size trait |
male |
0 days
| 3 |
47.2 |
fl |
0.81 |
1.4 |
automated blood analysis |
0.0 |
0 |
104875 |
2989 |
| SD-Fhem1+/- |
red blood cell distribution width-coefficient of variation |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte size trait |
female |
0 days
| 3 |
16.0 |
% |
0.69 |
1.2 |
automated blood analysis |
0.0 |
0 |
104916 |
2989 |
| SD-Fhem1+/- |
blood monocyte count to total leukocyte count ratio |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
monocyte quantity |
male |
0 days
| 3 |
3.3 |
% |
0.4 |
0.7 |
automated blood analysis |
0.0 |
0 |
104891 |
2989 |
| SD-Fhem1+/- |
blood aspartate aminotransferase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood aspartate transaminase amount |
male |
0 days
| 3 |
124.3 |
U/l |
5.6 |
9.7 |
automated blood analysis |
0.0 |
0 |
104931 |
2989 |
| SD-Fhem1+/- |
plasma indirect bilirubin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood bilirubin amount |
male |
0 days
| 3 |
-0.6 |
umol/l |
0.12 |
0.2 |
automated blood analysis |
0.0 |
0 |
104951 |
2989 |
| SD-Fhem1+/- |
blood uric acid level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood uric acid amount |
female |
0 days
| 3 |
2.83 |
mg/dl |
0.13 |
0.22 |
automated blood analysis |
0.0 |
0 |
104976 |
2989 |
| SD-Fhem1+/- |
platelet-large cell ratio |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
platelet size trait |
female |
0 days
| 3 |
16.1 |
% |
1.62 |
2.8 |
automated blood analysis |
0.0 |
0 |
104924 |
2989 |
| SD-Fhem1+/- |
blood alanine aminotransferase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood alanine transaminase amount |
male |
0 days
| 3 |
43.7 |
U/l |
3.29 |
5.7 |
automated blood analysis |
0.0 |
0 |
104927 |
2989 |
| SD-Fhem1+/- |
blood aspartate aminotransferase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood aspartate transaminase amount |
female |
0 days
| 3 |
100.5 |
U/l |
5.66 |
9.8 |
automated blood analysis |
0.0 |
0 |
104932 |
2989 |
| SD-Fhem1+/- |
blood creatine kinase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood creatine kinase amount |
male |
0 days
| 3 |
41.0 |
IU/l |
0.58 |
1.0 |
automated blood analysis |
0.0 |
0 |
104983 |
2989 |
| SD-Fhem1+/- |
blood eosinophil count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
eosinophil quantity |
male |
0 days
| 3 |
0.04 |
x 1000 cells/ul |
0.03 |
0.06 |
automated blood analysis |
0.0 |
0 |
104907 |
2989 |
| SD-Fhem1+/- |
platelet distribution width |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
platelet size trait |
female |
0 days
| 3 |
9.8 |
fl |
0.4 |
0.7 |
automated blood analysis |
0.0 |
0 |
104920 |
2989 |
| SD-Fhem1+/- |
platelet-large cell ratio |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
platelet size trait |
male |
0 days
| 3 |
11.7 |
% |
2.19 |
3.8 |
automated blood analysis |
0.0 |
0 |
104923 |
2989 |
| SD-Fhem1+/- |
blood gamma-glutamyltransferase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood gamma-glutamyltransferase amount |
male |
0 days
| 3 |
1.3 |
U/l |
0.35 |
0.6 |
automated blood analysis |
0.0 |
0 |
104935 |
2989 |
| SD-Fhem1+/- |
white blood cell count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
leukocyte quantity |
male |
0 days
| 3 |
3.2 |
x 1000 cells/ul |
0.52 |
0.9 |
automated blood cell counting method |
0.0 |
0 |
104835 |
2989 |
| SD-Fhem1+/- |
red blood cell count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte quantity |
female |
0 days
| 3 |
8.1 |
x 10E6 cells/ul |
0.17 |
0.3 |
automated blood cell counting method |
0.0 |
0 |
104840 |
2989 |
| SD-Fhem1+/- |
mean corpuscular hemoglobin concentration |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood hemoglobin amount |
male |
0 days
| 3 |
3443.0 |
g/dl |
23.67 |
41.0 |
automated blood analysis |
0.0 |
0 |
104883 |
2989 |
| SD-Fhem1+/- |
mean corpuscular hemoglobin concentration |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood hemoglobin amount |
female |
0 days
| 3 |
3433.0 |
g/dl |
12.7 |
22.0 |
automated blood analysis |
0.0 |
0 |
104884 |
2989 |
| SD-Fhem1+/- |
blood lymphocyte count to total leukocyte count ratio |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
lymphocyte quantity |
female |
0 days
| 3 |
57.8 |
% |
4.56 |
7.9 |
automated blood analysis |
0.0 |
0 |
104888 |
2989 |
| SD-Fhem1+/- |
blood monocyte count to total leukocyte count ratio |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
monocyte quantity |
female |
0 days
| 3 |
3.6 |
% |
0.46 |
0.8 |
automated blood analysis |
0.0 |
0 |
104892 |
2989 |
| SD-Fhem1+/- |
platelet distribution width |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
platelet size trait |
male |
0 days
| 3 |
8.9 |
fl |
0.58 |
1.0 |
automated blood analysis |
0.0 |
0 |
104919 |
2989 |
| SD-Fhem1+/- |
mean corpuscular hemoglobin |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood hemoglobin amount |
female |
0 days
| 3 |
17.7 |
pg |
0.23 |
0.4 |
automated blood analysis |
0.0 |
0 |
104880 |
2989 |
| SD-Fhem1+/- |
blood lymphocyte count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
lymphocyte quantity |
female |
0 days
| 3 |
1.8 |
x 1000 cells/ul |
0.29 |
0.5 |
automated blood analysis |
0.0 |
0 |
104900 |
2989 |
| SD-Fhem1+/- |
blood monocyte count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
leukocyte quantity |
female |
0 days
| 3 |
0.1 |
x 1000 cells/ul |
0.0 |
0.0 |
automated blood analysis |
0.0 |
0 |
104904 |
2989 |
| SD-Fhem1+/- |
blood eosinophil count to total leukocyte count ratio |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
eosinophil quantity |
male |
0 days
| 3 |
1.0 |
% |
0.52 |
0.9 |
automated blood analysis |
0.0 |
0 |
104895 |
2989 |
| SD-Fhem1+/- |
plasma direct bilirubin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood bilirubin amount |
female |
0 days
| 3 |
0.4 |
umol/l |
0.12 |
0.2 |
automated blood analysis |
0.0 |
0 |
104948 |
2989 |
| SD-Fhem1+/- |
blood protein measurement |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood total protein amount |
male |
0 days
| 3 |
640.0 |
g/dl |
7.51 |
13.0 |
automated blood analysis |
0.0 |
0 |
104955 |
2989 |
| SD-Fhem1+/- |
blood albumin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood albumin amount |
male |
0 days
| 3 |
339.0 |
g/dl |
5.2 |
9.0 |
automated blood analysis |
0.0 |
0 |
104959 |
2989 |
| SD-Fhem1+/- |
hematocrit |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte quantity |
female |
0 days
| 3 |
41.7 |
% |
0.92 |
1.6 |
automated blood analysis |
0.0 |
0 |
104860 |
2989 |
| SD-Fhem1+/- |
platelet count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
platelet quantity |
female |
0 days
| 3 |
964.3 |
x 1000 /ul |
62.24 |
107.8 |
automated blood analysis |
0.0 |
0 |
104864 |
2989 |
| SD-Fhem1+/- |
red blood cell distribution width-coefficient of variation |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte size trait |
male |
0 days
| 3 |
19.6 |
% |
0.81 |
1.4 |
automated blood analysis |
0.0 |
0 |
104915 |
2989 |
| SD-Fhem1+/- |
blood lymphocyte count to total leukocyte count ratio |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
lymphocyte quantity |
male |
0 days
| 3 |
50.7 |
% |
4.04 |
7.0 |
automated blood analysis |
0.0 |
0 |
104887 |
2989 |
| SD-Fhem1+/- |
blood eosinophil count to total leukocyte count ratio |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
eosinophil quantity |
female |
0 days
| 3 |
1.0 |
% |
0.06 |
0.1 |
automated blood analysis |
0.0 |
0 |
104896 |
2989 |
| SD-Fhem1+/- |
blood alanine aminotransferase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood alanine transaminase amount |
female |
0 days
| 3 |
35.8 |
U/l |
6.64 |
11.5 |
automated blood analysis |
0.0 |
0 |
104928 |
2989 |
| SD-Fhem1+/- |
white blood cell count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
leukocyte quantity |
female |
0 days
| 3 |
3.0 |
x 1000 cells/ul |
0.23 |
0.4 |
automated blood cell counting method |
0.0 |
0 |
104836 |
2989 |
| SD-Fhem1+/- |
blood glucose level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood glucose amount |
female |
0 days
| 3 |
108.0 |
mg/dl |
12.47 |
21.6 |
automated blood analysis |
0.0 |
0 |
104968 |
2989 |
| SD-Fhem1+/- |
blood alkaline phosphatase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood alkaline phosphatase amount |
male |
0 days
| 3 |
69.3 |
U/l |
2.6 |
4.5 |
automated blood analysis |
0.0 |
0 |
104939 |
2989 |
| SD-Fhem1+/- |
blood globulin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood globulin amount |
male |
0 days
| 3 |
301.0 |
g/dl |
6.35 |
11.0 |
automated blood analysis |
0.0 |
0 |
104963 |
2989 |
| SD-Fhem1+/- |
platelet count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
platelet quantity |
male |
0 days
| 3 |
1004.0 |
x 1000 /ul |
80.6 |
139.6 |
automated blood analysis |
0.0 |
0 |
104863 |
2989 |
| SD-Fhem1+/- |
mean platelet volume |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
platelet size trait |
female |
0 days
| 3 |
8.7 |
fl |
0.23 |
0.4 |
automated blood analysis |
0.0 |
0 |
104868 |
2989 |
| SD-Fhem1+/- |
mean corpuscular volume |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte size trait |
female |
0 days
| 3 |
51.4 |
fl |
0.64 |
1.1 |
automated blood analysis |
0.0 |
0 |
104876 |
2989 |
| SD-Fhem1+/- |
blood eosinophil count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
eosinophil quantity |
female |
0 days
| 3 |
0.03 |
x 1000 cells/ul |
0.0 |
0.0 |
automated blood analysis |
0.0 |
0 |
104908 |
2989 |
| SD-Fhem1+/- |
platelet-large cell ratio |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
platelet size trait |
male |
0 days
| 3 |
16.5 |
% |
1.44 |
2.5 |
automated blood analysis |
0.0 |
0 |
104921 |
2989 |
| SD-Fhem1+/- |
plasma indirect bilirubin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood bilirubin amount |
female |
0 days
| 3 |
-0.2 |
umol/l |
0.17 |
0.3 |
automated blood analysis |
0.0 |
0 |
104952 |
2989 |
| SD-Fhem1+/- |
blood globulin level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood globulin amount |
female |
0 days
| 3 |
305.0 |
g/dl |
4.62 |
8.0 |
automated blood analysis |
0.0 |
0 |
104964 |
2989 |
| SD-Fhem1+/- |
blood urea nitrogen level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood urea nitrogen amount |
female |
0 days
| 3 |
920.0 |
mg/dl |
57.74 |
100.0 |
automated blood analysis |
0.0 |
0 |
104972 |
2989 |
| SD-Fhem1+/- |
red blood cell count |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte quantity |
male |
0 days
| 3 |
8.9 |
x 10E6 cells/ul |
0.17 |
0.3 |
automated blood cell counting method |
0.0 |
0 |
104839 |
2989 |
| SD-Fhem1+/- |
blood creatine kinase activity level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood creatine kinase amount |
female |
0 days
| 3 |
34.5 |
IU/l |
3.23 |
5.6 |
automated blood analysis |
0.0 |
0 |
104984 |
2989 |
| SD-Fhem1+/- |
blood protein measurement |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood total protein amount |
female |
0 days
| 3 |
677.0 |
g/dl |
16.74 |
29.0 |
automated blood analysis |
0.0 |
0 |
104956 |
2989 |
| SD-Fhem1+/- |
blood glucose level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood glucose amount |
male |
0 days
| 3 |
129.6 |
mg/dl |
4.16 |
7.2 |
automated blood analysis |
0.0 |
0 |
104967 |
2989 |
| SD-Fhem1+/- |
blood urea nitrogen level |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
blood urea nitrogen amount |
male |
0 days
| 3 |
810.0 |
mg/dl |
28.87 |
50.0 |
automated blood analysis |
0.0 |
0 |
104971 |
2989 |
| SD-Fhem1+/- |
hematocrit |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte quantity |
male |
0 days
| 3 |
42.1 |
% |
0.92 |
1.6 |
automated blood analysis |
0.0 |
0 |
104859 |
2989 |
| SD-Fhem1+/- |
red blood cell distribution width- standard deviation |
control condition |
Yu D, et al., Oncotarget. 2016 Sep 20;7(38):61656-61669. doi: 10.18632/oncotarget.11429. |
erythrocyte size trait |
male |
0 days
| 3 |
28.0 |
% |
0.98 |
1.7 |
automated blood analysis |
0.0 |
0 |
104911 |
2989 |
